Cell Surface-Dependent Generation of Angiostatin4.5

Cancer Research

Volumn 64, Issue 1, 2004, Pages 162-168

  Wang, Hao ^a   Schultz, Ryan ^a   Hong, Jerome ^a   Cundiff, Deborah L ^a   Jiang, Keyi ^a   Soff, Gerald A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANGIOSTATIN; ANGIOSTATIN 4.5; ANTIBODY; BETA ACTIN; ENOLASE; ISOPROTEIN; LIPOCORTIN 2; MEMBRANE RECEPTOR; PLASMIN; PLASMINOGEN; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ALKALINITY; ANGIOGENESIS; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL FREE SYSTEM; CELL INVASION; CELL MEMBRANE; CELL SURFACE; CHEMICAL REACTION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; KRINGLE DOMAIN; METASTASIS; NEWBORN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; STOICHIOMETRY;

ADENOCARCINOMA; ANGIOSTATINS; CELL DIVISION; CELL MEMBRANE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; PLASMIN; PLASMINOGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 1642494842     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1862     Document Type: Article

References (58)

1. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
2. Folkman, J., and Klagsbrun, M. Angiogenic factors. Science (Wash. DC), 235: 442-447, 1987.
3. Burke, T. W., Hoskins, W. J., Heller, P. B., Bibro, M. C., Weiser, E. B., and Park, R. C. Prognostic factors associated with radical hysterectomy failure. Gynecol. Oncol., 26: 153-159, 1987.
4. Brem, S. S., Gullino, P. M., and Medina, D. Angiogenesis: a market for neoplastic transformation of mammary papillary hyperplasia. Science (Wash. DC), 195: 880-882, 1977.
5. Adcock, L. L., Julian, T. M., Okagaki, T., Jones, T. K., Prem, K. A., Twiggs, L. B., Potish, R. A., and Phillips, G. L. Carcinoma of the uterine cervix FIGO Stage I-B. Gynecol. Oncol., 14: 199-208, 1982.
6. Blood, C. H., and Zetter, B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta, 1032: 89-118, 1990.
7. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
8. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 84: 1875-1887, 1992.
9. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
10. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
11. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (Wash. DC), 284: 808-812, 1999.
12. Yancopoulos, G. D., Klagsbrun, M., and Folkman, J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell, 93: 661-664, 1998.
13. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA., 87: 6624-6628, 1990.
14. Volpert, O. V., Stellmach, V., and Bouck, N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat, 36: 119-126, 1995.
15. Torimura, T., Sata, M., Ueno, T., Kin, M., Tsuji, R., Suzaku, K., Hashimoto, O., Sugawara, H., and Tanikawa, K. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum. Pathol., 29: 986-991, 1998.
16. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
17. Castellino, F. J. Plasminogen. In: H. R. Roberts (ed.), Molecular Basis of Thrombosis and Hemostasis, pp. 495-515. New York: Marcel Dekker, 1995.
18. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 88: 801-810, 1997.
19. Lijnen, H. R., Ugwu, F., Bini, A., and Collen, D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry, 37: 4699-4702, 1998.
20. Patterson, B. C., and Sang, Q. A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem., 272: 28823-28825, 1997.
21. O'Reilly, M. S., Wiederschain, D., Steller-Stevenson, W. G., Folkman, J., and Moses, M. A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem., 274: 29568-29571, 1999.
22. Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., Kwaan, H. C., Lee, F., Kramer, R. A., Volpert, O., Bouck, N., and Soff, G. A. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA, 94: 10868-10872, 1997.
23. Gately, S., Twardowski, P., Stack, M. S., Patrick, M., Boggio, L., Cundiff, D. L., Schnaper, H. W., Madison, L., Volpert, O., Bouck, N., Enghild, J., Kwaan, H. C., and Soff, G. A. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res., 56: 4887-4890, 1996.
24. Soff, G. A. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev., 19: 97-107, 2000.
25. Stathakis, P., Lay, A. J., Fitzgerald, M., Schlieker, C., Matthias, L. J., and Hogg, P. J. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J. Biol. Chem., 274: 8910-8916, 1999.
26. Stathakis, P., Fitzgerald, M., Matthias, L. J., Chesterman, C. N., and Hogg, P. J. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J. Biol. Chem., 272: 20641-20645, 1997.
27. Cao, R., Wu, H. L., Veitonmaki, N., Linden, P., Farnebo, J., Shi, G. Y., and Cao, Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA, 96: 5728-5733, 1999.
28. Cao, Y., Veitonmaki, N., Keough, K., Cheng, H., Lee, L. S., and Zurakowski, D. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int. J. Mol. Med., 5: 547-551, 2000.
29. Lannutti, B. J., Gately, S. T., Quevedo, M. E., Soff, G. A., and Paller, A. S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res., 57: 5277-5280, 1997.
30. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
31. Waisman, D. M. Annexin II tetramer: structure and function. Mol. Cell Biochem, 149-150: 301-322, 1995.
32. Cesarman, G. M., Guevara, C. A., and Hajjar, K. A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem., 269: 21198-21203, 1994.
33. Hajjar, K. A., Jacovina, A. T., and Chacko, J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem., 269: 21191-21197, 1994.
34. Hawley, S. B., Green, M. A., and Miles, L. A. Discriminating between cell surface and intracellular plasminogen-binding proteins: heterogeneity in profibrinolytic plasminogen-binding proteins on monocytoid cells. Thromb. Haemost., 84: 882-890, 2000.
35. Kassam, G., Kwon, M., Yoon, C. S., Graham, K. S., Young, M. K., Gluck, S., and Waisman, D. M. Purification and characterization of A61. An angiostatin-like plasminogen fragment produced by plasmin autodigestion in the absence of sulfhydryl donors. J. Biol. Chem., 276: 8924-8933, 2001.
36. Kwon, M., Caplan, J. F., Filipenko, N. R., Choi, K. S., Fitzpatrick, S. L., Zhang, L., and Waisman, D. M. Identification of annexin II heterotetramer as a plasmin reductase. J. Biol. Chem., 277: 10903-10911, 2002.
37. Redlitz, A., Fowler, B. J., Plow, E. F., and Miles, L. A. The role of an enolase-related molecule in plasminogen binding to cells. Eur. J. Biochem., 227: 407-415, 1995.
38. Liu, L., Tao, J. Q., and Zimmerman, U. J. Annexin II binds to the membrane of A549 cells in a calcium-dependent and calcium-independent manner. Cell Signalling, 9: 299-304, 1997.
39. Dudani, A. K., and Ganz, P. R. Endothelial cell surface actin serves as it binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br. J. Haematol., 95: 168-178, 1996.
40. Andronicos, N. M., and Ranson, M. The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br. J. Cancer, 85: 909-916, 2001.
41. Herman, I. M. Actin isoforms. Curr. Opin. Cell Biol., 5: 48-55, 1993.
42. Lay, A. J., and Hogg, P. J. Measurement of reduction of disulfide bonds in plasmin by phosphoglycerate kinase. Methods Enzymol., 348: 87-92, 2002.
43. Lay, A. J., Jiang, X. M., Kisker. O., Flynn, E., Underwood, A., Condron, R., and Hogg, P. J. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase, Nature (Lond.), 408: 869-873, 2000.
44. Owen, M. J., Auger, J., Barber, B. H., Edwards, A. J., Walsh, F. S., and Crumpton, M. J. Actin may be present on the lymphocyte surface. Proc. Natl. Acad. Sci. USA, 75: 4484-4488, 1978.
45. Sanders, S. K., and Craig, S. W. A lymphocyte cell surface molecule that is antigenically related to actin. J. Immunol., 131: 370-377, 1983.
46. Pardridge, W. M., Nowlin, D. M., Choi, T. B., Yang, J., Calaycay, J., and Shively, J. E. Brain capillary 46, 000 dalton protein is cytoplasmic actin and is localized to endothelial plasma membrane. J. Cereb. Blood Flow Metab., 9: 675-680, 1989.
47. Moroianu, J., Fett, J. W., Riordan, J. F., and Vallee, B. L. Actin is a surface component of calf pulmonary artery endothelial cells in culture. Proc. Natl. Acad. Sci. USA, 90: 3815-3819, 1993.
48. Hu, G. F., Chang, S. I., Riordan, J. F., and Vallee, B. L. An angiogenin-binding protein from endothelial cells. Proc. Natl. Acad. Sci. USA, 88: 2227-2231, 1991.
49. Hu, G. F., and Riordan, J. F. Angiogenin enhances actin acceleration of plasminogen activation. Biochem. Biophys. Res. Commun., 197: 682-687, 1993.
50. Hu, G. F., Strydom, D. J., Fett, J. W., Riordan, J. F., and Vallee, B. L. Actin is a binding protein for angiogenin. Proc. Natl. Acad. Sci. USA, 90: 1217-1221, 1993.
51. St-Onge, D., and Gicquaud, C. Research on the mechanism of interaction between actin and membrane lipids. Biochem. Biophys. Res. Commun., 167: 40-47, 1990.
52. St-Onge, D., and Gicquaud, C. Evidence of direct interaction between actin and membrane lipids. Biochem. Cell Biol., 67: 297-300, 1989.
53. Gicquaud, C. Actin conformation is drastically altered by direct interaction with membrane lipids: a differential scanning calorimetry study. Biochemistry, 32: 11873-11877, 1993.
54. Gicquaud, C. Does actin bind to membrane lipids under conditions compatible with those existing in vivo? Biochem. Biophys. Res. Commun., 208: 1154-1158, 1995.
55. Gicquaud, C., and Wong, P. Mechanism of interaction between actin and membrane lipids: a pressure-tuning infrared spectroscopy study. Biochem. J., 303 (Pt 3): 769-774, 1994.
56. Wiggins, D. L., Granai, C. O., Steinhoff, M. M., and Calabresi, P. Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol, 56: 353-356, 1995.
57. Sidenius, N., and Blasi, F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev., 22: 205-222, 2003.
58. Mazar, A. P., Henkin, J., and Goldfarb, R. H. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis, 3: 15-32, 1999.